Shire PLC  

(Public, LON:SHP)   Watch this stock  
Find more results for SHP
5,540.00
+35.00 (0.64%)
May 22 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 5,485.00 - 5,566.25
52 week 3,330.00 - 5,755.00
Open 5,510.00
Vol / Avg. 729,930.00/1.33M
Mkt cap 32.43B*
P/E 15.58
Div/yield 12.51*
EPS 3.55*
Shares 591.65M
Beta     -
Inst. own     -
*GBP
Jul 23, 2015
Q2 2015 Shire PLC Earnings Release - 8:00AM GMT+1 - Add to calendar
Jun 2, 2015
Shire PLC at Jefferies Global Healthcare Conference - 3:00PM GMT+1 - Add to calendar
May 7, 2015
Shire PLC at Deutsche Bank Health Care Conference
Apr 30, 2015
Q1 2015 Shire PLC Earnings Call
Apr 30, 2015
Q1 2015 Shire PLC Earnings Release
Apr 28, 2015
Shire PLC Annual Shareholders Meeting
Mar 25, 2015
Shire PLC at Biotechnology Industry Organization (BIO) Asia International Conference
Mar 3, 2015
Shire PLC at Cowen Health Care Conference
  

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 126.05% 54.47%
Operating margin 30.53% 28.20%
EBITD margin - 41.79%
Return on average assets 63.31% 29.88%
Return on average equity 104.78% 46.80%
Employees 5,016 -
CDP Score - 91 B

Address

5 Riverwalk Citywest Business Campus, Dublin 24
DUBLIN,
Ireland
+353-1-4297700 (Phone)
+353-1-4297701 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Shire Plc is a specialty biopharmaceutical company that focuses on developing and marketing innovative specialty medicines that address unmet patient needs. The Company’s products included VYVANSE/VENVANSE (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), FOSRENOL (lanthanum carbonate), XAGRID (anagrelide hydrochloride), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant) and DERMAGRAFT(Human Fibroblast-Derived Dermal Substitute), CINRYZE. The Company focuses its development resources on projects in a number of therapeutic areas, including Neuroscience, Rare Diseases, Ophthalmology, Hematology and GI, and focuses its early development projects on rare diseases.

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Executive Director
Age: 57
Jeffrey Poulton Chief Financial Officer, Director
Age: 47
Ginger Gregory Chief Human Resource Officer
Mark J. Enyedy Interim General Counsel, Head of Corporate Development
Age: 51
Phil J. Vickers Head of Research and Development
Age: 55
Susan Saltzbart Kilsby Non-Executive Chairman of the Board
Age: 56
David J. Kappler Senior Independent Non-Executive Deputy Chairman of the Board
Age: 67
Dominic Blakemore Non-Executive Independent Director
Age: 45
William Burns Non-Executive Independent Director
Age: 67
Steven H. Gillis Ph.D. Non-Executive Independent Director
Age: 63